—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment
Excerpt from:
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Recommendation and review posted by Fredricko
